ArticleCPT: pharmacometrics & systems pharmacology2026
Utilizing Virtual Clinical Trials to Inform Target Coverage That Drives RSV Antiviral Efficacy.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) infection can result in a range of disease severity from mild upper respiratory tract symptoms to lower respiratory tract illness, with clinical manifestations dependent on age, co-morbidities, and immune status. At present, there is no antiviral approved for adults with RSV disease, and only one treatment option with limited utilization is available for pediatric patients. While several RSV antiviral candidates have demonstrated virological efficacy in healthy adult challenge studies, to date they have subsequently failed to show efficacy in patients. Mechanistically understanding the translation of efficacy from preclinical to challenge to patient studies is essential in addressing this unmet medical need in children and adults with RSV disease. This work uses a quantitative systems pharmacology (QSP) approach to mathematically represent the underlying pathophysiology of RSV infection to simulate and predict the effects of investigational direct acting RSV antiviral therapeutics. We developed virtual populations that capture viral load dynamics in viral challenge studies, where the participants are healthy adult volunteers, upon treatment with the F-protein inhibitor sisunatovir and the N-protein inhibitor zelicapavir. Due to underlying differences in dynamics between key populations, we also developed a pediatric patient virtual population to match the results from the zelicapavir pediatric Phase 2 study. This work projects that for a minimum coverage > 1× free EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.